Aurobindo Pharma declines 4% despite 23% YoY jump in June quarter profit

Interim dividend of Rs 1.25 per equity share of Re 1 has been approved by the board for FY21

Shares of Aurobindo Pharma dipped 4.47 per cent to Rs 892.25 on the BSE on Thursday despite the company reporting a 22.81 per cent year-on-year (YoY) rise in its consolidated net profit to Rs 780.68 crore for the quarter ended on June 30, 2020, mainly on account of robust sales in the US market.

Consolidated revenue from operations of the company stood at Rs 5,924.78 crore for the quarter under consideration. It was Rs 5,444.60 crore for the same period a year ago, Aurobindo Pharma said in a filing to BSE.

"Amid challenging times, we have started the financial year by reporting